Stockscreener 앱 받기
14.37
6.37%
0.86
전일 마감가:
$13.51
열려 있는:
$13.9
하루 거래량:
2.44M
Relative Volume:
1.08
시가총액:
$1.55B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-3.6658
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
+10.20%
1개월 성능:
+0.35%
6개월 성능:
+15.89%
1년 성능:
+89.08%
1일 변동 폭
$13.67
$14.54
1주일 범위
$13.04
$14.54
52주 변동 폭
$6.99
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.37 | 1.55B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Arcutis Grants 72,000 Restricted Stock Units to 9 New Hires: Key Details on 4-Year Vesting Plan - Stock Titan
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025 - Dermatology Times
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Benzinga
Road to RAD: What to Expect - Dermatology Times
ARQT Reveals Promising Long-Term Data for Zoryve in Atopic Derma - GuruFocus
Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - Seeking Alpha
Where are the Opportunities in (ARQT) - news.stocktradersdaily.com
Arcutis Biotherapeutics director Heron buys $30,246 in stock - Investing.com
Arcutis (ARQT) to Showcase New Data at 2025 RAD Conference | ARQ - GuruFocus
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast - GuruFocus
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference - The Manila Times
New Clinical Data: ZORYVE's Breakthrough 34-Week Skin Control for Children with Atopic Dermatitis - Stock Titan
Two Sigma Investments LP Cuts Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside - Seeking Alpha
H.C. Wainwright reiterates buy rating and $19 target on Arcutis stock - Investing.com
Transcript : Arcutis Biotherapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Nuveen Asset Management LLC Has $5.11 Million Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 5% – Time to Sell? - Defense World
Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock - simplywall.st
Ameriprise Financial Inc. Acquires 50,662 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics SVP sells $24,806 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP sells $24,806 in stock - Investing.com Australia
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Immuno-Dermatology Leader Arcutis Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Bank of America Corp DE - Defense World
Needham & Company LLC Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World
Arcutis wins FDA nod for Zoryve foam for plaque psoriasis - MSN
Analyst Expectations For Arcutis Biotherapeutics's Future - Benzinga
ARQT Analyst Reiterates Buy Rating with $20 Price Target | ARQT Stock News - GuruFocus
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - BioSpace
FDA approves roflumilast foam 0.3% for scalp, body psoriasis - Contemporary Pediatrics
FDA approves ZORYVE foam for plaque psoriasis treatment - Investing.com Australia
FDA Approves Arcutis' (ARQT) Zoryve Foam for Psoriasis Treatment - GuruFocus
Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval - marketscreener.com
FDA Approval Boosts Arcutis Biotherapeutics (ARQT) with New Psor - GuruFocus
Arcutis wins FDA nod for Zoryve foam in psoriasis (ARQT:NASDAQ) - Seeking Alpha
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older | ARQT Stock News - GuruFocus
FDA approves ZORYVE foam for plaque psoriasis treatment By Investing.com - Investing.com India
Understanding Roflumilast Foam's FDA Approval for Scalp and Body Psoriasis, with Jennifer Soung, MD - HCPLive
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - The Manila Times
Better Weight Loss Stock: Amgen or Viking Therapeutics? - The Globe and Mail
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
79,815 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Acquired by BNP Paribas Financial Markets - Defense World
The Manufacturers Life Insurance Company Sells 1,547 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
When the Price of (ARQT) Talks, People Listen - news.stocktradersdaily.com
ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus
New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arcutis Biotherapeutics Inc 주식 (ARQT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Heron Patrick J | Director |
Jun 05 '25 |
Buy |
13.41 |
378 |
5,069 |
24,802 |
| Matsuda Masaru | See Remarks |
May 28 '25 |
Sale |
13.78 |
1,800 |
24,807 |
202,599 |
1.21%
1.51%
자본화:
|
볼륨(24시간):